An evolving perspective on novel modified release drug delivery systems for inhalational therapy.
An evolving perspective on novel modified release drug delivery systems for inhalational therapy.
复制标题
DOI：
10.1080/17425247.2023.2175814
复制
发表时间：
2023-03
影响因子：
6.6
通讯作者：
Ahsan, Fakhrul
中科院分区：
文献类型：
--
作者：
Hye, Tanvirul;Moinuddin, Sakib M. M.;Sarkar, Tanoy;Nguyen, Trieu;Saha, Dipongkor;Ahsan, Fakhrul
关键词：
经肺部给药主要用于治疗各种呼吸系统疾病，包括哮喘、慢性阻塞性肺疾病、呼吸道感染和肺癌，以及肺血管疾病，如肺高压。为了治疗呼吸系统疾病，为了改善患者的依从性和更好的治疗结果，需要靶向、改良或控释的吸入制剂。本文综述了影响可吸入修饰释放制剂的重要因素，重点介绍了不同的制剂策略，包括溶出度控制系统、药物复合体、定点给药、药物-聚合物结合物、药物-聚合物基质系统、脂质基质颗粒、纳米系统以及可通过粘液纤毛系统和肺泡巨噬细胞绕过清除的制剂。吸入型改装释放制剂可以通过延长药物在肺部的滞留时间来潜在地减少给药频率。然而，从商业化的角度来看，可吸入、修饰或控制释放的药物输送系统仍未被开发和开发。本文介绍了吸入性控释制剂的现状，阐述了开发新技术的途径，以开发各种药物在吸入给药后具有定制释放曲线的新技术，并解释了与修改释放可吸入制剂的翻译可行性相关的挑战。
Drugs delivered via the lungs are predominantly used to treat various respiratory disorders, including asthma, chronic obstructive pulmonary diseases, respiratory tract infections and lung cancers, and pulmonary vascular diseases such as pulmonary hypertension. To treat respiratory diseases, targeted, modified or controlled release inhalation formulations are desirable for improved patient compliance and superior therapeutic outcome. This review summarizes the important factors that have an impact on the inhalable modified release formulation approaches with a focus toward various formulation strategies, including dissolution rate-controlled systems, drug complexes, site-specific delivery, drug-polymer conjugates, and drug-polymer matrix systems, lipid matrix particles, nanosystems, and formulations that can bypass clearance via mucociliary system and alveolar macrophages. Inhaled modified release formulations can potentially reduce dosing frequency by extending drug’s residence time in the lungs. However, inhalable modified or controlled release drug delivery systems remain unexplored and underdeveloped from the commercialization perspective. This review paper addresses the current state-of-the-art of inhaled controlled release formulations, elaborates on the avenues for developing newer technologies for formulating various drugs with tailored release profiles after inhalational delivery and explains the challenges associated with translational feasibility of modified release inhalable formulations.
登录
查看更多内容
影响因子：
56.9
作者：
Edwards, DA;Hanes, J;Langer, R
通讯作者：
Langer, R
影响因子：
5.8
作者：
Dufour, Gilles;Bigazzi, William;Evrard, Brigitte
通讯作者：
Evrard, Brigitte
影响因子：
5.4
作者：
Adorni, Greta;Seifert, Gerrit;Rossi, Alessandra
通讯作者：
Rossi, Alessandra
影响因子：
3.6
作者：
Daman, Zahra;Gilani, Kambiz;Barghi, Mohammad Ali
通讯作者：
Barghi, Mohammad Ali
影响因子：
10.8
作者：
Cook, RO;Pannu, RK;Kellaway, IW
通讯作者：
Kellaway, IW